BMN 673 is a potent inhibitor of the PARP enzyme family, particularly PARP1 and PARP2, which play key roles in DNA repair mechanisms. Its primary application lies in cancer therapy, especially in tumors with deficiencies in homologous recombination repair pathways, such as those with BRCA1 or BRCA2 mutations. By inhibiting PARP, BMN 673 induces synthetic lethality in these cancer cells, leading to selective tumor cell death while sparing normal cells. It has shown promising activity in preclinical models of breast, ovarian, and prostate cancers. Additionally, BMN 673 is being investigated for use in combination with other DNA-damaging agents like chemotherapy or radiation to enhance their antitumor effects. Its high potency and favorable pharmacokinetic profile make it a candidate for targeted therapies in precision oncology.